Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti‐TNF treatment in patients with rheumatoid arthritis

References

• Chan K. F., Siegel M. R., Lenardo J. M. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 2000; 13: 419–22
   PubMed Web of Science ®Google Scholar
• Walczak H., Krammer P. H. The CD95 (APO‐1/Fas) and the TRAIL (APO‐2L) apoptosis systems. Exp Cell Res 2000; 256: 58–66
   PubMed Web of Science ®Google Scholar
• Chicheportiche Y., Bourdon P. R., Xu H., Hsu Y. M., Scott H., Hession C., et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272: 32401–10
   PubMed Web of Science ®Google Scholar
• Marsters S. A., Sheridan J. P., Pitti R. M., Brush J., Goddard A., Ashkenazi A. Identification of a ligand for the death‐domain containing receptor Apo3. Curr Biol 1998; 8: 525–8
   PubMed Web of Science ®Google Scholar
• Nakayama M., Kayagaki N., Yamaguchi N., Okumura K., Yagita H. Involvement of TWEAK in interferon gamma‐stimulated monocyte cytotoxicity. J Exp Med 2000; 192: 1373–80
   PubMedGoogle Scholar
• Saitoh T., Nakayama M., Nakano H., Yagita H., Yamamoto N., Yamaoka S. TWEAK induces NF‐kappaB2 p100 processing and long‐lasting NF‐kappaB activation. J Biol Chem 2003; 278: 36005–12
   PubMed Web of Science ®Google Scholar
• Lynch C. N., Wang Y. C., Lund J. K., Chen Y. W., Leal J. A., Wiley S. R. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999; 274: 8455–9
   PubMed Web of Science ®Google Scholar
• Jakubowski A., Browning B., Lukashev M., Sizing I., Thompson J. S., Benjamin C. D., et al. Dual role for TWEAK in angiogenic regulation. J Cell Sci 2002; 115: 267–74
   PubMed Web of Science ®Google Scholar
• Harada N., Nakayama M., Nakano H., Fukuchi Y., Yagita H., Okumura K. Proinflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002; 299: 488–93
   PubMed Web of Science ®Google Scholar
• Donohue P. J., Richards C. M., Brown S. A., Hanscom H. N., Buschman J., Thangada S., et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF‐2 and VEGF‐A mitogenic activity. Arterioscler Thromb Vasc Biol 2003; 23: 594–600
   PubMed Web of Science ®Google Scholar
• Chicheportiche Y., Chicheportiche R., Sizing I., Thompson J., Benjamin C. B., Ambrose C., et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti‐TWEAK monoclonal antibodies. Arthritis Res 2002; 4: 126–33
   PubMedGoogle Scholar
• Xu H., Okamoto A., Ichikawa J., Ando T., Tasaka K., Masuyama K., et al. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL‐8 and GM‐CSF. Biochem Biophys Res Commun 2004; 318: 422–7
   PubMed Web of Science ®Google Scholar
• Kim S. H., Kang Y. J., Kim W. J., Woo D. K., Lee Y., Kim D. I., et al. TWEAK can induce proinflammatory cytokines and matrix metalloproteinase‐9 in macrophages. Circ J 2004; 68: 396–9
   PubMedGoogle Scholar
• Saas P., Boucraut J., Walker P. R., Quiquerez A. L., Billot M., Desplat‐Jego S., et al. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 2000; 32: 102–7
   PubMed Web of Science ®Google Scholar
• Campbell S., Michaelson J., Burkly L., Putterman C. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004; 9: 2273–84
   PubMed Web of Science ®Google Scholar
• Choy E. H., Panayi G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907–16
   PubMed Web of Science ®Google Scholar
• Harris E. D., Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277–89
   PubMed Web of Science ®Google Scholar
• Badolato R., Oppenheim J. J. Role of cytokines, acute‐phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum 1996; 26: 526–38
   PubMed Web of Science ®Google Scholar
• Zwerina J., Redlich K., Schett G., Smolen J. S. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci 2005; 1051: 716–29
   PubMed Web of Science ®Google Scholar
• Morita Y., Fukazawa T., Hirashima M., Kaga K., Kusaoi M., Morita T., et al. The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production. Scand J Rheumatol 2006; 35: 268–72
   PubMed Web of Science ®Google Scholar
• Cuchacovich M., Soto L., Edwardes M., Gutierrez M., Llanos C., Pacheco D. Tumour necrosis factor (TNF)alpha‐308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35: 435–40
   PubMed Web of Science ®Google Scholar
• Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602
   PubMed Web of Science ®Google Scholar
• Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A., et al. Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35–45
   PubMed Web of Science ®Google Scholar
• Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9
   PubMed Web of Science ®Google Scholar
• Qin S., Rottman J. B., Myers P., Kassam N., Weinblatt M., Loetscher M., et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746–54
   PubMed Web of Science ®Google Scholar
• Loetscher P., Uguccioni M., Bordoli L., Baggiolini M., Moser B., Chizzolini C., et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998; 391: 344–5
   PubMed Web of Science ®Google Scholar
• Mack M., Bruhl H., Gruber R., Jaeger C., Cihak J., Eiter V., et al. Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis. Arthritis Rheum 1999; 42: 981–8
   PubMed Web of Science ®Google Scholar
• Kamata K., Kamijo S., Nakajima A., Koyanagi A., Kurosawa H., Yagita H., et al. Involvement of TNF‐like weak inducer of apoptosis in the pathogenesis of collagen‐induced arthritis. J Immunol 2006; 177: 6433–9
   PubMed Web of Science ®Google Scholar
• Perper S. J., Browning B., Burkly L. C., Weng S., Gao C., Giza K., et al. TWEAK is a novel arthritogenic mediator. J Immunol 2006; 177: 2610–20
   PubMed Web of Science ®Google Scholar
• Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• van der Linden S., Valkenburg H. A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8
   PubMed Web of Science ®Google Scholar
• Prevoo M. L., van't Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B., van Riel P. L. Modified disease activity scores that include twenty‐eight‐joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8
   PubMed Web of Science ®Google Scholar
• Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–91
   PubMed Web of Science ®Google Scholar
• Kaptein A., Jansen M., Dilaver G., Kitson J., Dash L., Wang E., et al. Studies on the interaction between TWEAK and the death receptor WSL‐1/TRAMP (DR3). FEBS Lett 2000; 485: 135–41
   PubMedGoogle Scholar
• Wiley S. R., Cassiano L., Lofton T., Davis‐Smith T., Winkles J. A., Lindner V., et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15: 837–46
   PubMed Web of Science ®Google Scholar
• Polek T. C., Talpaz M., Darnay B. G., Spivak‐Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem 2003; 278: 32317–23
   PubMed Web of Science ®Google Scholar
• Chicheportiche Y., Fossati‐Jimack L., Moll S., Ibnou‐Zekri N., Izui S. Down‐regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun 2000; 279: 162–5
   PubMedGoogle Scholar
• Pradet‐Balade B., Medema J. P., Lopez‐Fraga M., Lozano J. C., Kolfschoten G. M., Picard A., et al. An endogenous hybrid mRNA encodes TWE–PRIL, a functional cell surface TWEAK–APRIL fusion protein. EMBO J 2002; 21: 5711–20
   PubMed Web of Science ®Google Scholar
• Nakayama M., Ishidoh K., Kayagaki N., Kojima Y., Yamaguchi N., Nakano H., et al. Multiple pathways of TWEAK‐induced cell death. J Immunol 2002; 168: 734–43
   PubMed Web of Science ®Google Scholar
• Schneider P., Schwenzer R., Haas E., Muhlenbeck F., Schubert G., Scheurich P., et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol 1999; 29: 1785–92
   PubMed Web of Science ®Google Scholar